Medicare Part D continues to cover certain GLP-1 medications for approved uses such as diabetes, cardiovascular disease, MASH, and obstructive sleep apnea
Cellcept (mycophenolate mofetil): Used to prevent organ rejection, requires a 6-week deferral
Fuels Enzymes Fuels enzymes that convert carbohydrates, fats, and proteins into usable energy for daily performance
Increasing Investment in R&D Increasing investment in R&D is another major factor driving the growth of the GLP-1 targeted peptide weight loss drugs market, as it accelerates the development of more effective, longer-acting, and patient-friendly therapies
Technological Advancements in Supplement Formulation The L Carnitine Market is witnessing advancements in supplement formulation technology, which enhances the efficacy and bioavailability of L Carnitine Market products